Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigation

Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model

Megan Minnix, Vikram Adhikarla, Enrico Caserta, Erasmus Poku, Russell Rockne, John E. Shively and Flavia Pichiorri
Journal of Nuclear Medicine June 2021, 62 (6) 795-801; DOI: https://doi.org/10.2967/jnumed.120.251983
Megan Minnix
1Department of Molecular Imaging and Therapy, Beckman Research Institute, City of Hope, Duarte, California
2Irell and Manella Graduate School of Biological Sciences, Beckman Research Institute, City of Hope, Duarte, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vikram Adhikarla
3Department of Computational and Quantitative Medicine, Division of Mathematical Oncology, Beckman Research Institute, City of Hope, Duarte, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enrico Caserta
4Briskin Myeloma Center and Department of Hematologic Malignancies Research Institute, City of Hope, Duarte, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erasmus Poku
5Radiopharmacy, City of Hope, Duarte, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Russell Rockne
3Department of Computational and Quantitative Medicine, Division of Mathematical Oncology, Beckman Research Institute, City of Hope, Duarte, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John E. Shively
1Department of Molecular Imaging and Therapy, Beckman Research Institute, City of Hope, Duarte, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Flavia Pichiorri
4Briskin Myeloma Center and Department of Hematologic Malignancies Research Institute, City of Hope, Duarte, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 62 no. 6 795-801
DOI 
https://doi.org/10.2967/jnumed.120.251983
PubMed 
33127621

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication June 19, 2020
  • Accepted for publication October 7, 2020
  • Published online June 1, 2021.

Article Versions

  • previous version (October 30, 2020 - 14:32).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Megan Minnix*,1,2,
  2. Vikram Adhikarla*,3,
  3. Enrico Caserta*,4,
  4. Erasmus Poku5,
  5. Russell Rockne3,
  6. John E. Shively1 and
  7. Flavia Pichiorri4
  1. 1Department of Molecular Imaging and Therapy, Beckman Research Institute, City of Hope, Duarte, California
  2. 2Irell and Manella Graduate School of Biological Sciences, Beckman Research Institute, City of Hope, Duarte, California
  3. 3Department of Computational and Quantitative Medicine, Division of Mathematical Oncology, Beckman Research Institute, City of Hope, Duarte, California
  4. 4Briskin Myeloma Center and Department of Hematologic Malignancies Research Institute, City of Hope, Duarte, California; and
  5. 5Radiopharmacy, City of Hope, Duarte, California
  1. For correspondence or reprints contact: John E. Shively, Beckman Research Institute, City of Hope, 1500 E. Duarte Rd., Duarte, CA 91010. E-mail: jshively{at}coh.org
  1. ↵* Contributed equally to this work.

View Full Text

Statistics from Altmetric.com

Cited By...

  • 25 Citations
  • 27 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053
    Cheng Wang, Yumei Chen, Yun Nan Hou, Qiufang Liu, Di Zhang, Haitao Zhao, You Zhang, Shuxian An, Lianghua Li, Jian Hou, Gang Huang, Jianjun Liu, Yong Juan Zhao, Weijun Wei
    European Journal of Nuclear Medicine and Molecular Imaging 2021 48 9
  • 64Cu-labeled daratumumab F(ab′)2 fragment enables early visualization of CD38-positive lymphoma
    Lei Kang, Cuicui Li, Qi Yang, Logan Sutherlin, Lin Wang, Zhao Chen, Kaelyn V. Becker, Nan Huo, Yongkang Qiu, Jonathan W. Engle, Rongfu Wang, Chengzhi He, Dawei Jiang, Xiaojie Xu, Weibo Cai
    European Journal of Nuclear Medicine and Molecular Imaging 2022 49 5
  • A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma
    Elodie Duray, Margaux Lejeune, Frederic Baron, Yves Beguin, Nick Devoogdt, Ahmet Krasniqi, Yoline Lauwers, Yong Juan Zhao, Matthias D’Huyvetter, Mireille Dumoulin, Jo Caers
    Journal of Hematology & Oncology 2021 14 1
  • The paradoxical role of radiation‐induced cGAS–STING signalling network in tumour immunity
    Xiaoyi Zhang, Han Zhang, Jiajia Zhang, Mengdie Yang, Mengqin Zhu, Yuzhen Yin, Xin Fan, Fei Yu
    Immunology 2023 168 3
  • CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma
    Kim De Veirman, Janik Puttemans, Ahmet Krasniqi, Thomas Ertveldt, Heleen Hanssens, Ema Romao, Dirk Hose, Cleo Goyvaert, Philip Vlummens, Serge Muyldermans, Karine Breckpot, Frank Bruchertseifer, Alfred Morgenstern, Matthias D’Huyvetter, Nick Devoogdt
    OncoImmunology 2021 10 1
  • A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy
    Vikram Adhikarla, Dennis Awuah, Alexander B. Brummer, Enrico Caserta, Amrita Krishnan, Flavia Pichiorri, Megan Minnix, John E. Shively, Jeffrey Y. C. Wong, Xiuli Wang, Russell C. Rockne
    Cancers 2021 13 20
  • Cure of Disseminated Human Lymphoma with [225Ac]Ac-Ofatumumab in a Preclinical Model
    Mark S. Longtine, Kyuhwan Shim, Mark J. Hoegger, Nadia Benabdallah, Diane S. Abou, Daniel L.J. Thorek, Richard L. Wahl
    Journal of Nuclear Medicine 2023 64 6
  • Radiotheranostic Agents in Hematological Malignancies
    Jo Caers, Elodie Duray, Louise Vrancken, Guillaume Marcion, Valentina Bocuzzi, Kim De Veirman, Ahmet Krasniqi, Margaux Lejeune, Nadia Withofs, Nick Devoogdt, Mireille Dumoulin, Amelie Eriksson Karlström, Matthias D’Huyvetter
    Frontiers in Immunology 2022 13
  • Designing combination therapies for cancer treatment: application of a mathematical framework combining CAR T-cell immunotherapy and targeted radionuclide therapy
    Vikram Adhikarla, Dennis Awuah, Enrico Caserta, Megan Minnix, Maxim Kuznetsov, Amrita Krishnan, Jefferey Y. C. Wong, John E. Shively, Xiuli Wang, Flavia Pichiorri, Russell C. Rockne
    Frontiers in Immunology 2024 15
  • CD38 as theranostic target in oncology
    Valentina Bocuzzi, Jessica Bridoux, Michelle Pirotte, Nadia Withofs, Roland Hustinx, Matthias D’Huyvetter, Jo Caers, Guillaume Marcion
    Journal of Translational Medicine 2024 22 1

Article usage

Article usage: October 2020 to April 2025

AbstractFullPdf
Oct 202010706
Nov 2020584059
Dec 2020161016
Jan 2021135011
Feb 2021107010
Mar 2021154011
Apr 2021176021
May 2021105033
Jun 20219316782
Jul 20213953233
Aug 20211611821
Sep 20211441717
Oct 20211781036
Nov 20211201038
Dec 2021466575
Jan 2022485558
Feb 2022452814
Mar 2022293631
Apr 20223412538
May 2022266930
Jun 2022243528
Jul 2022324634
Aug 2022233728
Sep 2022163225
Oct 2022204217
Nov 2022192518
Dec 2022273113
Jan 2023173222
Feb 2023182519
Mar 2023142426
Apr 202341546
May 2023151621
Jun 2023152515
Jul 20235911
Aug 2023121314
Sep 202382215
Oct 20231111020
Nov 2023719011
Dec 2023113923
Jan 2024274630
Feb 2024185729
Mar 202496167
Apr 2024168832
May 202497018
Jun 2024186927
Jul 20241310625
Aug 2024119839
Sep 202493813
Oct 2024133621
Nov 2024174614
Dec 202495620
Jan 202595523
Feb 2025159424
Mar 2025158740
Apr 2025127549
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (6)
Journal of Nuclear Medicine
Vol. 62, Issue 6
June 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model
Megan Minnix, Vikram Adhikarla, Enrico Caserta, Erasmus Poku, Russell Rockne, John E. Shively, Flavia Pichiorri
Journal of Nuclear Medicine Jun 2021, 62 (6) 795-801; DOI: 10.2967/jnumed.120.251983

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model
Megan Minnix, Vikram Adhikarla, Enrico Caserta, Erasmus Poku, Russell Rockne, John E. Shively, Flavia Pichiorri
Journal of Nuclear Medicine Jun 2021, 62 (6) 795-801; DOI: 10.2967/jnumed.120.251983
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Targeted Alpha Therapy with [225Ac]Ac-Macropa-Isatuximab for CD38-positive Hematological Malignancies
  • Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
  • Cure of Disseminated Human Lymphoma with [225Ac]Ac-Ofatumumab in a Preclinical Model
  • Improved Tumor Responses with Sequential Targeted {alpha}-Particles Followed by Interleukin 2 Immunocytokine Therapies in Treatment of CEA-Positive Breast and Colon Tumors in CEA Transgenic Mice
  • Google Scholar

More in this TOC Section

  • 212Bi-Macroaggregated Albumin Inhibited Mouse Melanoma Growth by Regulating Cell Cycle Checkpoint Markers Without Promoting Living Cell Repopulation
  • In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with [11C]HSP990 in Healthy Aging and Neurodegeneration
  • 161Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas
Show more Basic Science Investigation

Similar Articles

Keywords

  • CD38
  • daratumumab
  • multiple myeloma
  • radioimmunotherapy
  • mathematic modeling
SNMMI

© 2025 SNMMI

Powered by HighWire